Rescue of defective MC4R cell-surface expression and signaling by a novel pharmacoperone Ipsen 17

Journal of Molecular Endocrinology

Volumn 53, Issue 1, 2014, Pages 17-29

  Wang, Xiao Hua ^a   Wang, Hao Meng ^a   Zhao, Bao Lei ^a   Yu, Peng ^a   Fan, Zhen Chuan ^a,b  

^a TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Obesita and Algaegen LLC   (United States)

Author keywords

Functional rescue; Melanocortin; Pharmacological chaperone; Receptor; Severe early onset morbid obesity

Indexed keywords

ALPHA INTERMEDIN; CYCLIC AMP; HORMONE RECEPTOR BLOCKING AGENT; IPSEN 17; MELANOCORTIN 4 RECEPTOR; UNCLASSIFIED DRUG; 2-(2-(2-(5-BROMO-2-METHOXYPHENYL)ETHYL)-3-FLUOROPHENYL)-4,5-DIHYDRO-1H-IMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; MC4R PROTEIN, HUMAN; MUTANT PROTEIN;

ARTICLE; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENCY; GENE MUTATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; MORBID OBESITY; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE; AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; GENETIC VARIABILITY; GENETICS; METABOLISM; MUTATION;

ALPHA-MSH; AMINO ACID SUBSTITUTION; BENZIMIDAZOLES; CELL MEMBRANE; CYCLIC AMP; GENETIC VARIATION; HEK293 CELLS; HUMANS; IMIDAZOLES; MUTANT PROTEINS; MUTATION; OBESITY, MORBID; RECEPTOR, MELANOCORTIN, TYPE 4; SIGNAL TRANSDUCTION;

EID: 84903607979     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0005     Document Type: Article

References (47)

1. Bernier V, Bichet DG & Bouvier M 2004a Pharmacological chaperone action on G-protein-coupled receptors. Current Opinion in Pharmacology 4 528-533. (doi:10.1016/j.coph.2004.08.001)
2. Bernier V, Lagace M, Bichet DG & Bouvier M 2004b Pharmacological chaperones: potential treatment for conformational diseases. Trends in Endocrinology and Metabolism 15 222-228. (doi:10.1016/j.tem.2004. 05.003)
3. Bernier V, LagaceM, Lonergan M, Arthus MF, Bichet DG& BouvierM2004c Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Molecular Endocrinology 18 2074-2084. (doi:10.1210/me. 2004-0080)
4. Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperriere A, Brouard R, Bouvier M et al. 2006 Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. Journal of the American Society of Nephrology 17 232-243. (doi:10.1681/ASN.2005080854)
5. Buono P, Pasanisi F, Nardelli C, Ieno L, Capone S, Liguori R, Finelli C, Oriani G, Contaldo F & Sacchetti L 2005 Six novel mutations in the proopiomelanocortin and melanocortin receptor 4 genes in severely obese adults living in southern Italy. Clinical Chemistry 51 1358-1364. (doi:10.1373/clinchem.2005.047886)
6. Chaipatikul V, Erickson-Herbrandson LJ, Loh HH & Law PY 2003 Rescuing the traffic-deficient mutants of rat m-opioid receptors with hydrophobic ligands. Molecular Pharmacology 64 32-41. (doi:10.1124/mol.64.1.32)
7. Chen C & Okayama H 1987 High-efficiency transformation of mammalian cells by plasmid DNA. Molecular and Cellular Biology 7 2745-2752. (doi:10.1128/MCB.7.8.2745)
8. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L et al. 2000 Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nature Genetics 26 97-102. (doi:10.1038/79254)
9. Cone RD 2005 Anatomy and regulation of the central melanocortin system. Nature Neuroscience 8 571-578. (doi:10.1038/nn1455)
10. Conn PM & Ulloa-Aguirre A 2010 Trafficking of G-protein-coupled receptors to the plasmamembrane: insights for pharmacoperone drugs. Trends in Endocrinology and Metabolism 21 190-197. (doi:10.1016/j.tem. 2009.11.003)
11. Conn PM, Ulloa-Aguirre A, Ito J & Janovick JA 2007 G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacological Reviews 59 225-250. (doi:10.1124/pr.59.3.2)
12. Dong B & Fan ZC 2013 Functional rescue of obesity-causing human melanocortin-4 receptor mutants: insights for pharmacological chaperon drugs. Translational Medicine 3 e123. (doi:10.4172/2161-1025.1000e123)
13. Dubern B, Clement K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B & Tounian P 2001 Mutational analysis of melanocortin-4 receptor, agouti-related protein, and a-melanocyte-stimulating hormone genes in severely obese children. Journal of Pediatrics 139 204-209. (doi:10.1067/mpd.2001.116284)
14. Fan ZC & Tao YX 2009 Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. Journal of Cellular and Molecular Medicine 13 3268-3282. (doi:10.1111/j.1582-4934.2009.00726.x)
15. Fan J, Perry SJ, Gao Y, Schwarz DA & Maki RA 2005 A point mutation in the human melanin concentrating hormone receptor 1 reveals an important domain for cellular trafficking. Molecular Endocrinology 19 2579-2590. (doi:10.1210/me.2004-0301)
16. Fan ZC, Sartin JL & Tao YX 2008 Molecular cloning and pharmacological characterization of porcine melanocortin-3 receptor. Journal of Endocrinology 196 139-148. (doi:10.1677/JOE-07-0403)
17. Farooqi S & O'Rahilly S 2006 Genetics of obesity in humans. Endocrine Reviews 27 710-718. (doi:10.1210/er.2006-0040)
18. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T & O'Rahilly S 2000 Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. Journal of Clinical Investigation 106 271-279. (doi:10.1172/JCI9397)
19. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T & O'Rahilly S 2003 Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. New England Journal of Medicine 348 1085-1095. (doi:10.1056/NEJMoa022050)
20. Granell S, Mohammad S, Ramanagoudr-Bhojappa R & Baldini G 2010 Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Molecular Endocrinology 24 1805-1821. (doi:10.1210/me.2010-0071)
21. Hainerova I, Larsen LH, Holst B, Finkova M, Hainer V, Lebl J, Hansen T & Pedersen O 2007 Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. Journal of Clinical Endocrinology and Metabolism 92 3689-3696. (doi:10.1210/ jc.2007-0352)
22. Hawtin SR 2006 Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor. Journal of Biological Chemistry 281 14604-14614. (doi:10.1074/jbc.M511610200)
23. Hinney A, Schmidt A, Nottebom K, Heibult O, Becker I, Ziegler A, Gerber G, Sina M, Gorg T, Mayer H et al. 1999 Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. Journal of Clinical Endocrinology and Metabolism 84 1483-1486. (doi:10.1210/jcem.84.4.5728)
24. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD et al. 1997 Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 131-141. (doi:10.1016/S0092-8674(00)81865-6)
25. Janovick JA, Maya-Nunez G & Conn PM 2002 Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. Journal of Clinical Endocrinology and Metabolism 87 3255-3262. (doi:10.1210/jcem.87.7.8582)
26. Janovick JA, Goulet M, Bush E, Greer J, Wettlaufer DG & Conn PM 2003 Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. Journal of Pharmacology and Experimental Therapeutics 305 608-614. (doi:10.1124/jpet.102.048454)
27. Knollman PE, Janovick JA, Brothers SP & Conn PM 2005 Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropin-releasing hormone receptor mutants. Journal of Biological Chemistry 280 24506-24514. (doi:10.1074/jbc.M501978200)
28. Kobayashi H, Ogawa Y, Shintani M, Ebihara K, Shimodahira M, Iwakura T, Hino M, Ishihara T, Ikekubo K, Kurahachi H et al. 2002 A novel homozygous missense mutation of melanocortin-4 receptor (MC4R) in a Japanese woman with severe obesity. Diabetes 51 243-246. (doi:10.2337/diabetes.51.1.243)
29. Lubrano-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, Zhang S, Bertrais S, Hercberg S, Basdevant A, Clement K et al. 2006 Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. Journal of Clinical Endocrinology and Metabolism 91 1811-1818. (doi:10.1210/ jc.2005-1411)
30. Mo X-L & Tao Y-X 2013 Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors. Biochimica et Biophysica Acta 1832 1939-1948. (doi:10.1016/j.bbadis.2013.06.006)
31. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG et al. 2000 Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. Journal of Clinical Investigation 105 887-895. (doi:10.1172/JCI8688)
32. Nijenhuis WA, Garner KM, van Rozen RJ & Adan RA 2003 Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. Journal of Biological Chemistry 278 22939-22945. (doi:10.1074/jbc.M211326200)
33. Noorwez SM, Kuksa V, Imanishi Y, Zhu L, Filipek S, Palczewski K & Kaushal S 2003 Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. Journal of Biological Chemistry 278 14442-14450. (doi:10.1074/jbc.M300087200)
34. Noorwez SM, Malhotra R, McDowell JH, Smith KA, Krebs MP & Kaushal S 2004 Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. Journal of Biological Chemistry 279 16278-16284. (doi:10.1074/jbc.M312101200)
35. Petaja-Repo UE, Hogue M, Bhalla S, Laperriere A, Morello JP & Bouvier M 2002 Ligands act as pharmacological chaperones and increase the efficiency of d opioid receptor maturation. EMBO Journal 21 1628-1637. (doi:10.1093/emboj/21.7.1628)
36. Poitout L, Brault V, Sackur C, Bernetière S, Camara J, Plas P & Roubert P 2007 Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor. Bioorganic & Medicinal Chemistry Letters 17 4464-4470. (doi:10.1016/ j.bmcl.2007.06.010)
37. Rene P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, Valenzano KJ & Bouvier M 2010 Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. Journal of Pharmacology and Experimental Therapeutics 335 520-532. (doi:10.1124/jpet.110.172098)
38. Robben JH, Sze M, Knoers NV & Deen PM 2006 Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Molecular Biology of the Cell 17 379-386. (doi:10.1091/ mbc.E05-06-0579)
39. Robben JH, Sze M, Knoers NV & Deen PM 2007 Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. American Journal of Physiology. Renal Physiology 292 F253-F260. (doi:10.1152/ ajprenal.00247.2006)
40. Robert J, Auzan C, Ventura MA & Clauser E 2005 Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone. Journal of Biological Chemistry 280 42198-42206. (doi:10.1074/ jbc.M510180200)
41. Spiegelman BM & Flier JS 2001 Obesity and the regulation of energy balance. Cell 104 531-543. (doi:10.1016/S0092-8674(01)00240-9)
42. Tan K, Pogozheva ID, Yeo GS, Hadaschik D, Keogh JM, Haskell-Leuvano C, O'Rahilly S, Mosberg HI & Farooqi IS 2009 Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 150 114-125. (doi:10.1210/ en.2008-0721)
43. Tao YX 2005 Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Molecular and Cellular Endocrinology 239 1-14. (doi:10.1016/j.mce.2005.04.012)
44. Tao YX 2006 Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacology & Therapeutics 111 949-973. (doi:10.1016/j.pharmthera. 2006.02.008)
45. Tao YX 2010 The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocrine Reviews 31 506-543. (doi:10.1210/ er.2009-0037)
46. Ulloa-Aguirre A & Michael Conn P 2011 Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G proteincoupled receptors. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 5 13-24. (doi:10.2174/187221411794351851)
47. Vos TJ, Caracoti A, Che JL, Dai M, Farrer CA, Forsyth NE, Drabic SV, Horlick RA, Lamppu D, Yowe DL et al. 2004 Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. Journal of Medicinal Chemistry 47 1602-1604. (doi:10.1021/jm034244g)